FDA Drug Shortages

Current and Resolved Drug Shortages and Discontinuations Reported to FDA

Start Over | Back to Previous Screen

Mecasermin [rDNA origin] (Increlex) Injection
Status: Currently in Shortage
»Date first posted: 04/26/2012
»Therapeutic Categories: Endocrinology/Metabolism; Pediatric

Ipsen Biopharmaceuticals Inc. (Revised 08/01/2016)

Company Contact Information:
866-435-5677

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
INCRELEX (mecasermin [rDNA origin] injection), 10 mg/mL (NDC-15054-1040-5) Limited supply available. In conjunction with FDA, Ipsen Biopharmaceuticals, Inc. is making available INCRELEX Lot# 441453F. This lot was produced at an alternate manufacturing facility that has not been approved by the FDA. Please see the Dear Healthcare Provider Letter for additional product and supply information. Contact Ipsen Biopharmaceuticals, Inc. regarding product availability.

Dear HCP Letter Lot 441453F expiry extension

Shortage of an active ingredient

Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English